Fracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 μg) in Patients with Osteoporosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The purpose of this prospective, open-label, observational study was to assess the fracture preventing effect of Maxmarvil® tablets (alendronate 5 mg + calcitriol 0.5 μg) in patients with osteoporosis and to evaluate the change in bone mineral density (BMD) at the minimum 1-year follow-up. Methods: In this multicenter observational study, 691 patients with osteoporosis (aged 50 years or older) were treated with alendronate 5 mg + calcitriol 0.5 μg/day during their normal course of care. Patients were assessed at baseline and at 6 and 12 months. Baseline characteristics (including age, gender, concomitant disease, and baseline fractures) were evaluated. Results: From among the 848 participants, 149 individuals were lost to follow-up at the time of the study and 8 people had died. The 691 participants (54 men and 637 women) finished the follow-up study and completed the questionnaire. The mean age of the participants was 71.5 years (range, 50-92 years; mean age, 72.3 years for men and 71.4 years for women). Osteoporotic fracture occurred in 19 patients (2.7%). BMD of the lumbar spine and hip was improved by 5% and 1.5% at the latest follow-up. At the latest follow-up, 24 patients (3.5%) complained of drug-related complications such as dyspepsia, constipation, and nausea. Conclusions: This prospective observational study demonstrated that alendronate 5 mg + calcitriol 0.5 μg/day had a preventive effect on osteoporotic fracture and it increased the BMD of the lumbar spine by 5% at the latest follow-up.
Abstract
Background: The purpose of this prospective, open-label, observational study was to assess the fracture preventing effect of Maxmarvil® tablets (alendronate 5 mg + calcitriol 0.5 μg) in patients with osteoporosis and to evaluate the change in bone mineral density (BMD) at the minimum 1-year follow-up. Methods: In this multicenter observational study, 691 patients with osteoporosis (aged 50 years or older) were treated with alendronate 5 mg + calcitriol 0.5 μg/day during their normal course of care. Patients were assessed at baseline and at 6 and 12 months. Baseline characteristics (including age, gender, concomitant disease, and baseline fractures) were evaluated. Results: From among the 848 participants, 149 individuals were lost to follow-up at the time of the study and 8 people had died. The 691 participants (54 men and 637 women) finished the follow-up study and completed the questionnaire. The mean age of the participants was 71.5 years (range, 50-92 years; mean age, 72.3 years for men and 71.4 years for women). Osteoporotic fracture occurred in 19 patients (2.7%). BMD of the lumbar spine and hip was improved by 5% and 1.5% at the latest follow-up. At the latest follow-up, 24 patients (3.5%) complained of drug-related complications such as dyspepsia, constipation, and nausea. Conclusions: This prospective observational study demonstrated that alendronate 5 mg + calcitriol 0.5 μg/day had a preventive effect on osteoporotic fracture and it increased the BMD of the lumbar spine by 5% at the latest follow-up.
참고문헌 (19)
- Ha YC, "Current trends and future projections of hip fracture in South Korea using nationwide claims data", Osteoporos Int, 27, pp.2603~2609 (2016)
- 이성락, "Morbidity and Mortality in Jeju Residents over 50-Years of Age with Hip Fracture with Mean 6-Year Follow-Up: A Prospective Cohort Study", Journal of Korean Medical Science, 28(7), pp.1089~1094 (2013), 대한의학회
- Madureira MM, "Quality of life measurements in patients with osteoporosis and fractures", Clinics, 67, pp.1315~1320 (2012)
- Abimanyi-Ochom J, "Changes in quality of life associated with fragility fractures: Australian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (AusICUROS)", Osteoporos Int, 26, pp.1781~1790 (2015)
- Park C, "The incidence and residual lifetime risk of osteoporosis-related fractures in Korea", J Bone Miner Metab, 29, pp.744~751 (2011)
- Peng J, "Bisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: A meta-analysis", Pak J Med Sci, 32, pp.499~504 (2016)
- Center JR, "Osteoporosis medication and reduced mortality risk in elderly women and men", J Clin Endocrinol Metab, 96, pp.1006~1014 (2011)
- Cree MW, "Mortality and morbidity associated with osteoporosis drug treatment following hip fracture", Osteoporos Int, 14, pp.722~727 (2003)
- Wells GA, "Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women", Cochrane Database Syst Rev, 1, pp.CD001155~ (2008)
- Wells G, "Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women", Cochrane Database Syst Rev, 1, pp.CD004523~ (2008)
- Zhou J, "Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses", Osteoporos Int, 27, pp.3289~3300 (2016)
- Rhee Y, "Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study", Osteoporos Int, 17, pp.1801~1807 (2006)
- Watts NB, "Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database", J Manag Care Pharm, 10, pp.142~151 (2004)
- Foster SA, "Fractures in women treated with raloxifene or alendronate: a retrospective database analysis", BMC Womens Health, 13, pp.15~ (2013)
- Modi A, "Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment", Curr Med Res Opin, 31, pp.767~777 (2015)
- Iwamoto J, "Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis", J Bone Miner Metab, 23, pp.238~242 (2005)
- Bonnick S, "Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years", J Clin Endocrinol Metab, 91, pp.2631~2637 (2006)
- Tan W, "Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis", J Clin Pharm Ther, 41, pp.519~523 (2016)
- 서희원, "The Efficacy and Safety of a Combined Alendronate and Calcitriol Agent (Maxmarvil): A Postmarketing Surveillance Study in Korean Postmenopausal Women with Osteoporosis", Korean Journal of Family Medicine, 33(6), pp.346~355 (2012), 대한가정의학회